Ainos, Inc. Reports 97% Revenue Decline in Q2 2026, Focuses on AI Nose Technology

Ainos, Inc. reported a significant decline in financial performance for the second quarter and first half of 2026, as detailed in its latest 10-Q filing. The company generated revenues of $152,000 for the three months ended June 30, 2026, a decrease of 97% compared to $4.7 million in the same period last year. For the first half of 2026, revenues totaled $313,000, down from $110.9 million in the first half of 2025. The drop in revenue was primarily attributed to lower sales volumes of VELDONA pet supplements as the company shifts its operational focus towards its AI Nose platform.

The company's operating expenses increased to $4.4 million in Q2 2026, up 17% from $3.7 million in Q2 2025. This rise was driven by a 39% increase in selling, general, and administrative expenses, which reached $2.5 million, largely due to higher share-based compensation and professional fees. Research and development expenses remained relatively stable, decreasing slightly to $1.9 million from $1.9 million year-over-year. Ainos reported a net loss of $4.6 million for Q2 2026, a 12% increase from the $4.1 million loss in Q2 2025.

In terms of strategic developments, Ainos has been focusing on advancing its AI Nose technology, which is designed for industrial applications, including semiconductor manufacturing and healthcare environments. The company has engaged in partner-led deployments and is working on expanding its product offerings. As of June 30, 2026, Ainos had cash and cash equivalents of $1.4 million, a significant increase from $417,000 at the end of 2025, primarily due to proceeds from a loan agreement and an at-the-market offering.

Operationally, Ainos has seen changes in its customer engagement metrics, with a strategic pivot towards industrial applications impacting its revenue streams. The company has also been actively involved in research and validation activities related to its AI Nose technology, which are at various stages of deployment. The total employee headcount has not been disclosed, but the company continues to invest in its workforce to support its growth strategy.

Looking ahead, Ainos anticipates continued investment in product development and clinical trial activities to advance its pipeline. The company plans to leverage its cash reserves and potential financing options to fund operations over the next twelve months. However, Ainos has acknowledged the uncertainty surrounding its ability to secure additional financing, which could impact its operational plans and overall financial health.